NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...
Why would this be the case? The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor Agonist to help obesity patients lose weight is already established. Not only that ...
Share on Pinterest GLP-1 drugs may protect the brain from inflammation, some studies say, but others warn they may increase depression risk. Image credit: James Manning – PA Images/Getty Images.
When Trova Wine and Market shut its doors last month after nearly five years in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like Ozempic.
Working with a weight management program can help sustain the use of GLP-1 therapies and address potential side effects. Patient education and expectation management are crucial for maximizing ...
Feb. 12, 2024 – People with type 2 diabetes taking GLP-1 medicines may experience potentially blinding eye conditions as soon as the day after starting the drugs, and eye doctors are now asking ...
Research shows that people on GLP-1 medications are ditching processed foods and buying more nutrient-dense ones like fresh produce, beans and yogurt. (Photo illustrations: Yahoo News; photos ...
Dr Almandoz discusses the important considerations for women with obesity who are using GLP-1 therapies and may be considering pregnancy or are currently pregnant. The clip highlights the ...
In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for weight loss, among others) has caused demand to skyrocket ...
The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control. The stock has ...
Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat obesity. While many drugs in this class are relatively new, researchers ...